证券代码：688639 证券简称：华恒生物 公告编号：2025-006 安徽华恒生物科技股份有限公司 2025 年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 1、 公司在任董事 9 人，出席 9 人； 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 162 | | --- | --- | | 普通股股东人数 | 162 | | 2、出席会议的股东所持有的表决权数量 | 119,612,063 | | 普通股股东所持有表决权数量 | 119,612,063 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 47.99 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 47.99 | 注：截至股权登记日，公司总股本为 249,723,997 股，其中公司回购专户中的股份数量为 49 ...

安徽华恒生物科技股份有限公司 2025 年第一次临时股东大会会议资料 2025年第一次临时股东大会会议须知 证券代码：688639 证券简称：华恒生物 安徽华恒生物科技股份有限公司 2025 年第一次临时股东大会 会议资料 中国合肥 二〇二五年三月 安徽华恒生物科技股份有限公司 2025 年第一次临时股东大会会议资料 2025 年第一次临时股东大会会议资料 目 录 | 2025 年第一次临时股东大会会议须知 1 | | --- | | 2025 年第一次临时股东大会会议议程 3 | | 议案一：关于增加公司募投项目实施内容的议案 4 | 安徽华恒生物科技股份有限公司 2025 年第一次临时股东大会会议资料 为了维护安徽华恒生物科技股份有限公司（以下简称"公司"）全体股东的 合法权益，确保股东大会的正常秩序和议事效率，保证股东大会的顺利进行，根 据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》 （以下简称"《证券法》"）《上市公司股东大会规则》以及《安徽华恒生物科技股 份有限公司章程》《安徽华恒生物科技股份有限公司股东大会议事规则》等相关 规定，特制定 2025 年第一次临时股东大会 ...

兴业证券股份有限公司 关于安徽华恒生物科技股份有限公司 增加募投项目实施内容的核查意见 兴业证券股份有限公司（以下简称"兴业证券"或"保荐机构"）作为安 徽华恒生物科技股份有限公司（以下简称"华恒生物"或"公司"）向特定对 象发行 A 股股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上海 证券交易所科创板股票上市规则》《上市公司监管指引第 2 号——上市公司募 集资金管理和使用的监管要求》《上海证券交易所科创板上市公司自律监管指 引第 1 号——规范运作》等有关法律法规和规范性文件的要求，对华恒生物增 加募投项目实施内容事项进行了审慎核查，并出具本核查意见，具体核查情况 如下： 一、募集资金及投资项目基本情况 此次募集资金到账前，公司已根据项目进度使用自筹资金预先投入募投项 目。公司以自筹资金实际已投入募投项目的金额合计为 106,550.22 万元，截至 本核查意见披露之日，已置换金额为 68,380.91 万元，具体情况如下： 单位：万元 | 序号 | | 项目名称 | 拟投入募集 资金 | 自筹资金预先 投入金额 | 置换金额 | | --- | --- | --- | --- | --- | ...

证券代码：688639 证券简称：华恒生物 公告编号：2025-003 安徽华恒生物科技股份有限公司 关于增加募投项目实施内容的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 募集资金及投资项目基本情况 （一）募集资金基本情况 经中国证券监督管理委员会出具的《关于同意安徽华恒生物科技股份有限公 司向特定对象发行股票注册的批复》（证监许可〔2024〕988 号），公司获准向 特定对象发行股票。公司本次向特定对象发行人民币普通股（A 股）21,122,510 股，每股发行价格为人民币 33.14 元，募集资金人民币 699,999,981.40 元，扣除 各项发行费用人民币 16,190,921.91 元（不含增值税），实际募集资金净额为人民 币 683,809,059.49 元。前述募集资金已于 2024 年 10 月 21 日全部到位，业经容 1 本次拟调整的项目名称：年产 5 万吨生物基丁二酸及生物基产品原料生 产基地建设项目（以下简称"丁二酸项目"）和年产 5 万吨生物基苹果酸 生产建设项目 ...

证券代码：688639 证券简称：华恒生物 公告编号：2025-004 （一） 股东大会类型和届次 2025 年第一次临时股东大会 安徽华恒生物科技股份有限公司 关于召开 2025 年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 3 月 25 日 14 点 00 分 召开地点：合肥市高新区长安路 197 号公司 A1 会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2025 年 3 月 25 日 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回 ...

证券代码:688639 证券简称:华恒生物 公告编号:2025-005 经与会监事审议，议案表决结果如下： （一）审议通过《关于增加公司募投项目实施内容的议案》 安徽华恒生物科技股份有限公司 第四届监事会第十五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 监事会会议召开情况 安徽华恒生物科技股份有限公司（以下简称"公司"）第四届监事会第十五 次会议于 2025 年 3 月 7 日在公司会议室以现场会议结合通讯方式召开。本次会 议应到监事 3 人，实到监事 3 人。会议通知已于 2025 年 2 月 28 日以专人递送方 式送达全体监事。会议由监事会主席刘洋召集和主持。本次会议的召集、召开符 合《中华人民共和国公司法》和《公司章程》的有关规定。 二、 监事会会议审议情况 公司本次新增募投项目实施内容是结合公司实际经营情况及发展战略所作 出的审慎决策，符合《上市公司监管指引第 2 号——上市公司募集资金管理和使 用的监管要求》《上海证券交易所科创板股票上市规则》等法律法规、规范性文 件的规定，不存在损害 ...

Investment Rating - The investment rating for the company is "Outperform" (maintained) [1] Core Views - The report highlights that the decline in valine prices has put pressure on profits, but there is potential for performance improvement with the ramp-up of new products [1][8] - The company is expected to see a turning point in performance in 2025 as new products are launched and valine prices stabilize [8] Financial Data and Profit Forecast - Total revenue is projected to grow from 1,938 million in 2023 to 4,462 million by 2026, with a CAGR of approximately 36.8% [2] - The net profit attributable to the parent company is expected to decrease significantly in 2024 to 200 million, before rebounding to 363 million in 2025 and 565 million in 2026 [2] - The gross margin is forecasted to stabilize around 28.7% in 2025, with a slight increase to 29.7% by 2026 [2] Market Data - As of February 28, 2025, the closing price of the stock is 31.54 yuan, with a market capitalization of 7,202 million [3] - The stock has experienced a significant price fluctuation over the past year, with a high of 130.50 yuan and a low of 26.11 yuan [3] Company Performance Insights - The company reported a total revenue of 2.184 billion for 2024, reflecting a year-on-year growth of 12.7%, but a significant decline in net profit by 55.5% [8] - The report indicates that the decline in valine prices and increased competition have adversely affected profitability, but new product launches are expected to provide growth opportunities [8] - The company is actively working on ramping up production of new products such as arginine and tryptophan, which are anticipated to contribute positively to future revenues [8]

Financial Performance - Total revenue for 2024 reached RMB 218,444.68 million, an increase of 12.70% compared to RMB 193,826.81 million in the previous year[4] - Operating profit decreased by 58.98% to RMB 20,954.85 million from RMB 51,090.33 million year-on-year[4] - Net profit attributable to shareholders of the parent company fell by 55.51% to RMB 19,978.17 million from RMB 44,906.15 million in the previous year[4] - Basic earnings per share decreased by 56.12% to RMB 0.86 from RMB 1.96 year-on-year[4] Assets and Equity - Total assets increased by 25.57% to RMB 498,524.26 million from RMB 397,023.81 million at the beginning of the period[4] - Shareholders' equity attributable to the parent company rose by 40.94% to RMB 257,492.09 million from RMB 182,697.12 million at the beginning of the period[4] - The company issued new shares, raising a net amount of RMB 684 million, contributing to the increase in equity[8] Profit Decline Factors - The decline in profits was primarily due to a decrease in the price of valine products and an increase in related expenses[7][8] - Weighted average return on equity decreased by 16.89 percentage points to 10.17% from 27.06% year-on-year[4] Market Response - The company is actively responding to market demand and competition, leading to sustained growth in product sales despite the profit decline[7]

Investment Rating - The report maintains an "Outperform" rating for the company [1] Core Views - The company is expected to see a turning point in its performance in 2025, driven by stabilized valine prices and the ramp-up of new projects [1][8] - The company has faced significant profit declines in 2024 due to falling prices of valine and challenges in new product launches [8] - The company is actively advancing project construction and testing, with new products expected to contribute to growth in 2025 [8] Financial Data and Earnings Forecast - Total revenue is projected to grow from 1,938 million in 2023 to 3,231 million in 2025, reflecting a growth rate of 53.8% [7] - Net profit attributable to the parent company is expected to recover from 203 million in 2024 to 363 million in 2025, with a growth rate of 78.4% [7] - The company anticipates a significant increase in earnings per share from 0.81 in 2024 to 1.45 in 2025 [7] - The gross margin is expected to stabilize around 28.6% in 2025, up from 27.9% in 2024 [7] Investment Analysis - The report maintains the profit forecast for 2024-2026 at 2.03 billion, 3.63 billion, and 5.65 billion respectively, with corresponding price-to-earnings ratios of 33, 18, and 12 [8]

Revenue Projections - The company expects 2024 annual revenue to be between 2.1 billion and 2.3 billion CNY, an increase of 161.73 million to 361.73 million CNY, representing a year-on-year growth of 8.34% to 18.66%[4]. - In 2023, the company achieved a total profit of 506.27 million CNY and revenue of 1.938 billion CNY[7]. Profit Projections - The projected net profit attributable to shareholders for 2024 is expected to be between 180 million and 220 million CNY, a decrease of 229.06 million to 269.06 million CNY, reflecting a year-on-year decline of 51.01% to 59.92%[4]. - The estimated net profit attributable to shareholders after deducting non-recurring gains and losses for 2024 is expected to be between 170 million and 210 million CNY, a decrease of 228.09 million to 268.09 million CNY, indicating a year-on-year decrease of 52.07% to 61.20%[4]. - The net profit attributable to shareholders in 2023 was 449.06 million CNY, with a net profit after deducting non-recurring gains and losses of 438.09 million CNY[7]. Market and Operational Insights - The company anticipates continued growth in product sales in 2024, responding to market demand and competition[8]. - Increased operational scale has led to higher related expenses compared to the previous year, impacting overall profit[8]. - The price of valine products has decreased due to intensified market competition, affecting the company's profitability[8]. Forecast Accuracy - There are no significant uncertainties affecting the accuracy of this earnings forecast[9]. - The forecast data is preliminary and subject to final confirmation in the official 2024 annual report[10].